… It would be reasonable to infer that in the group with a %FVC of <60% in this study, the
patients were more responsive to the effect of pirfenidone because of the greater degree of FVC …

… , ERS, JRS, and ALAT clinical guideline on ILD, this systematic review looks at the existing
literature to determine whether patients with non-IPF PPF should be treated with pirfenidone. …

… therapeutic potential for IPF (23–25). Prompted by the encouraging results of an open label
prospective phase II clinical study of pirfenidone in patients … in favor of pirfenidone treatment …

… of 435 patients were assigned to pirfenidone 2403 mg/day, 87 to pirfenidone 1197 mg/day,
and 174 to placebo. In study 006, 171 of 344 patients were assigned to pirfenidone 2403 mg/…

… pirfenidone the ASCEND study[15] was performed in IPF patients who received pirfenidone
… relative reduction of 47.9% in the proportion of patients who had an absolute decline of ≥10…

… pirfenidone’s data sheet indicates this drug for the treatment of mild to moderate IPF, our
patients had, at the time they started pirfenidone, … study, our patients receiving pirfenidone had a …

… effects, and patients treated with pirfenidone must be carefully … with pirfenidone as a
pharmacologic therapy for patients with … pirfenidone into a treatment algorithm for patients with IPF, …

… pirfenidone is a valuable agent for use in patients with IPF. … of pirfenidone therapy, adherence
(≥80 % of the therapeutic … At month 6, persistency (patients continuing treatment) was at …

… Pirfenidone has been shown to slow disease progression in patients with idiopathic …
the efficacy and safety of pirfenidone in patients with four non-IPF progressive fibrotic ILDs. …

… targeted population of Polish patients with IPF receiving pirfenidone treatment in the setting
of therapeutic program refunded by the National Health Fund (NHF) for patients with the mild-…